immunotherapy Archives - malecare.org

Towards An Understanding Of The Possible Future Role Of Combining Chemotherapy With Immunotherapy – On The Horizon

There was a study published in the journal Nature that described a promising new combination therapy for the treatment of men with advanced prostate cancers that are non-responsive to chemotherapy. The study is entitled "Immunosuppressive Plasma Cells Impede T-Cell Dependent Immunogenic Chemotherapy." The study was conducted at the University of California, San Diego. Prostate cancers [...]

By Malecare|2017-10-19T10:47:20-04:00May 29th, 2015|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials & Research, Combination Therapy, Immunosuppressive B cells, oxaliplatin, Research, Uncategorized|0 Comments

A Real Role for Immunotherapy in the Treatment of Advanced Prostate Cancer

Immunotherapy has a major and expanding role in the treatment of cancer, including advanced prostate cancer. Over time there have been a number of naysayers as the immunotherapy Provenge has played the role whipping boy by critics. The common criticism leveled at Provenge can be summed up simply, “It doesn’t work.” The plain truth is [...]

By Malecare|2017-10-19T10:47:29-04:00March 26th, 2015|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, immunotherapy, ipilimumab, Prostvac, Uncategorized, vaccines, Yervoy|3 Comments

Malecare Adds A New Teleconference About Immunotherapy and Advanced Prostate Cancer

Malecare announces the addition of our latest and informative teleconference about Immunotherapy and Advanced Prostate Cancer. Joining me in the conference is Dr. Nicholas J. Vogelzang, M.D., a medical oncologist with the Comprehensive Cancer Centers of Nevada (CCCN) and serves as chair and site research leader, and as medical director of the Developmental Therapeutics Committee and Member [...]

By Malecare|2020-02-04T11:32:03-05:00April 28th, 2014|Advanced Prostate Cancer, Drugs & Treatments, General Information, immunotherapy, ipilimumab, Prostvac, Provenge, teleconferences, vaccines|1 Comment

Yervoy (ipilimumab) Fails to Extend Survival in Men with mCRP Who Failed Chemo

Some bad news was reported today. Results from the Phase 3 randomized, double-blind clinical trial (Study 043) comparing Yervoy 10 mg/kg (ipilimumab) (n=399) to placebo (n=400) following radiation in men with advanced metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel showed no increase in overall survival. Yervoy is an immunotherapy which [...]

By Malecare|2017-10-19T10:49:29-04:00September 12th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, ipilimumab, Uncategorized, Understanding APC, Yervoy|0 Comments

Worthy New Immunotherapy Clinical Trial Opens at Johns Hopkins University for Men Thinking of Surgery

The exciting thing about Provenge is not only the real survival advantage that it offers with minimal side effects, but that it is a proof of concept treatment that is heralding in the potential future of many other immunotherapies. Today, we have two new possible treatments in active phase 3 trials, Prostvac and Yervoy. [...]

By Malecare|2021-02-17T10:43:31-05:00August 19th, 2013|Advanced Prostate Cancer, Bio Chemical Recurrence, Clinical Trials, Clinical Trials, GVAC, Uncategorized, vaccines|0 Comments

Teleconference – A New PROSPECT for Prostate Cancer Patients this Tuesday at 6 p.m.

Malecare will be holding a free teleconference this Tuesday, April 30 at 6.m. I will be speaking with Dr. James Gulley who is the Deputy Chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute and the Director of the Clinical Trials Group. He also serves as a Senior Investigator within [...]

By Malecare|2013-04-26T15:03:25-04:00April 26th, 2013|Advanced Prostate Cancer, Drugs & Treatments, Firmagon (degarelix), ipilimumab, MDV3100, NIH, Prostate Ponderings, Provenge, Research, Uncategorized, Understanding APC, vaccines, Xtandi, Yervoy, Zytiga|9 Comments

Looking Forward To The Promise Of Immunotherapy

As I have discussed, immunological therapy will be a significant cancer treatment option in the future, but how will it actually develop and what will it look like? Provenge (sipuleucel-T), for the treatment of men with advanced prostate cancer, was the first FDA approved autologous immunologic vaccine therapy for any type of cancer. However, Provenge [...]

By Malecare|2017-10-19T10:51:19-04:00March 20th, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, vaccines|2 Comments

Bavarian Nordic Initiates Pivotal Phase 3 Trial of PROSTVAC® Prostate Cancer Immunotherapy

Bavarian Nordic A/S (BAVA) announced on November 15, that its subsidiary, BN ImmunoTherapeutics has started the pivotal Phase 3 trial of PROSTVAC® for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The trial is being conducted under a Special Protocol Assessment agreement with the FDA. Notice this trial has the same criteria as [...]

By Malecare|2021-02-17T10:28:06-05:00January 17th, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, On The Horizon, Prostvac, Uncategorized, vaccines|0 Comments

CME Advisory Committee Supports Medicare Payments for Provenge for Men Meeting the FDA Guidelines

The Centers for Medicare and Medicaid Services (CME) decided to review their policies pertaining to paying for Provenge, which costs $93,000 per man. Since the hearings which were held a number of months ago, we have not heard any feedback. Despite this, most of the regions have been paying for the treatment, however there have [...]

By Malecare|2011-03-30T23:12:20-04:00March 30th, 2011|Advanced Prostate Cancer, Drugs & Treatments, Financial, Politics of Cancer, Provenge, Uncategorized|0 Comments

On the Horizon – The Current State of Affairs in Prostate Cancer Immunotherapy

Since the approval of Provenge in April of 2010 the pipeline of new potential immunotherapy drugs has swelled. For excellent reasons, many of us are very optimistic about the future. […]